HC Wainwright Reiterates “Buy” Rating for BridgeBio Pharma (NASDAQ:BBIO)

HC Wainwright reiterated their buy rating on shares of BridgeBio Pharma (NASDAQ:BBIOFree Report) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $43.00 price target on the stock.

BBIO has been the topic of several other research reports. Citigroup lifted their target price on shares of BridgeBio Pharma from $42.00 to $46.00 and gave the company a buy rating in a report on Friday, February 23rd. Raymond James started coverage on shares of BridgeBio Pharma in a report on Thursday, March 21st. They set an outperform rating and a $45.00 target price on the stock. Evercore ISI started coverage on shares of BridgeBio Pharma in a report on Tuesday, May 14th. They set an outperform rating and a $50.00 target price on the stock. UBS Group reduced their target price on shares of BridgeBio Pharma from $51.00 to $47.00 and set a buy rating on the stock in a report on Tuesday, May 28th. Finally, Mizuho cut their price objective on shares of BridgeBio Pharma from $60.00 to $53.00 and set a buy rating on the stock in a report on Tuesday, March 5th. Two equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of Moderate Buy and an average price target of $47.62.

View Our Latest Research Report on BBIO

BridgeBio Pharma Stock Down 2.9 %

Shares of BBIO opened at $28.01 on Thursday. The firm has a market cap of $5.24 billion, a PE ratio of -8.70 and a beta of 1.08. The company’s fifty day moving average is $27.87 and its two-hundred day moving average is $32.11. BridgeBio Pharma has a fifty-two week low of $13.26 and a fifty-two week high of $44.32.

BridgeBio Pharma (NASDAQ:BBIOGet Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.35. The company had revenue of $211.12 million during the quarter, compared to analyst estimates of $140.06 million. As a group, equities research analysts anticipate that BridgeBio Pharma will post -3.2 earnings per share for the current year.

Institutional Investors Weigh In On BridgeBio Pharma

Hedge funds and other institutional investors have recently modified their holdings of the stock. YHB Investment Advisors Inc. bought a new stake in shares of BridgeBio Pharma in the 1st quarter worth about $34,000. Quarry LP bought a new stake in shares of BridgeBio Pharma in the 4th quarter worth about $50,000. EntryPoint Capital LLC bought a new stake in shares of BridgeBio Pharma in the 1st quarter worth about $117,000. Assetmark Inc. increased its position in shares of BridgeBio Pharma by 46.8% in the 4th quarter. Assetmark Inc. now owns 2,931 shares of the company’s stock worth $118,000 after purchasing an additional 935 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of BridgeBio Pharma in the 3rd quarter worth about $132,000. Institutional investors own 99.85% of the company’s stock.

BridgeBio Pharma Company Profile

(Get Free Report)

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

Recommended Stories

Analyst Recommendations for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.